NCT02574728 2026-03-02
AflacST1502
Emory University
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT02641314 2024-05-10
METRO-NB2012
University of Cologne
Phase 2 Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00047281 2017-07-11
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00047294 2017-07-11
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00068770 2015-03-18
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00357500 2014-10-01
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01756989 2014-05-08
ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors
Helsinki University Central Hospital
Phase 2 Completed
NCT00504660 2012-01-11
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
M.D. Anderson Cancer Center
Phase 2 Completed